Haemonetics Co. (NYSE:HAE) Shares Sold by Keeley Teton Advisors LLC

Keeley Teton Advisors LLC cut its position in Haemonetics Co. (NYSE:HAE) by 13.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,490 shares of the medical instruments supplier’s stock after selling 870 shares during the period. Keeley Teton Advisors LLC’s holdings in Haemonetics were worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Covestor Ltd increased its holdings in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics in the 4th quarter valued at about $62,000. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares in the last quarter. AlphaQuest LLC lifted its stake in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,826 shares during the last quarter. Finally, KBC Group NV increased its stake in Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 712 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Price Performance

Shares of NYSE HAE opened at $56.89 on Thursday. The stock has a fifty day moving average price of $63.22 and a 200 day moving average price of $73.07. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market cap of $2.86 billion, a PE ratio of 22.40, a P/E/G ratio of 1.11 and a beta of 0.41.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HAE. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Needham & Company LLC decreased their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Raymond James reissued a “strong-buy” rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.